Tesamorelin (CAS 218949-48-5) – Wholesale & Research Grade
Tesamorelin, a synthetic analog of growth hormone-releasing hormone (GHRH), is primarily recognized for its applications in the treatment of lipodystrophy in HIV-infected patients. This peptide stimulates the endogenous release of growth hormone, leading to a reduction in visceral fat and an improvement in metabolic health. Its therapeutic potential has prompted extensive research into its effects on body composition and metabolic parameters.
Research Applications
Researchers have utilized tesamorelin in various studies to explore its efficacy not only in HIV-associated lipodystrophy but also in conditions related to obesity and metabolic syndrome. Clinical trials have demonstrated its capacity to enhance fat loss and improve insulin sensitivity, highlighting its role as a potential therapeutic agent beyond its initial indications. Additionally, tesamorelin has been investigated for its effects on cognitive function, as elevated growth hormone levels may contribute to improved cognitive performance in aging individuals.
Mechanism of Action
The mechanism of action of tesamorelin involves the stimulation of the pituitary gland to release growth hormone, which subsequently promotes lipolysis and inhibits lipogenesis. This leads to a favorable shift in body composition by decreasing visceral adipose tissue. Consequently, the peptide's ability to modulate growth hormone levels makes it a key subject of interest for further research into metabolic health interventions.
Solubility and Storage Advice
Tesamorelin is soluble in water, which facilitates its use in various experimental setups. For optimal stability, it should be stored in a lyophilized form at -20°C or lower, protected from moisture and light. Once reconstituted, it is advisable to use it within a short timeframe to maintain its potency, ideally within a week if stored at 2-8°C.
Future Research Directions
Future investigations are likely to focus on the broader applications of tesamorelin in metabolic health, particularly in older populations and those with obesity-related complications. Moreover, exploring its combination with other therapeutic agents may yield insights into synergistic effects that could enhance its efficacy. As research continues, tesamorelin may emerge as a versatile candidate for addressing various metabolic disorders.
| CAS Number | 218949-48-5 |
|---|---|
| Formula | C221H366N72O67S |
| Mol. Weight | 5136 g/mol |
| IUPAC Name | (4S)-4-[[2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S... |
| Grade | HPLC ≥98% |
Synthesis & Storage
Tesamorelin is supplied as a lyophilized powder to ensure stability during transit.
For long-term storage of CAS 218949-48-5, we recommend maintaining at -20°C.
Researchers must reconstitute this peptide with bacteriostatic water or sterile solvent only when ready for use.
Quality Control: All batches undergo rigorous HPLC purity testing (≥98%) prior to dispatch from our USA fulfillment center.